Yu Ping, He Xuan, Lu Fei, Li Ling, Song Huahua, Bian Xiaolan
Department of Pharmacy, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Medical Lab Technician, Experimental Nuclear Medicine Laboratory, Core Facility of Basic Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
J Thorac Dis. 2022 Aug;14(8):3016-3029. doi: 10.21037/jtd-22-897.
Lung cancer is the main cause of cancer-related death worldwide, and its incidence rate is high. Traditional methods of lung cancer screening, such as those based on X-ray, low-dose computed tomography (LDCT), positron emission computed tomography (PET/CT), electronic bronchoscopy, and serum tumor markers were not satisfied with the urgent need in improving the patient survival rate. Thus, biomarkers for early diagnosis and prognosis of lung cancer are extremely needed. Studies have identified a variety of long-chain non-coding RNAs (lncRNAs) that are expressed at abnormal levels in patients with lung cancer which was believed as a potential biomarker for the diagnosis and prognostic evaluation of lung cancer. This review aims to discuss the role of lncRNAs in non-small cell lung cancer (NSCLC), so as to provide insights into the prognosis of lung cancer.
We searched PubMed database of the related scientific researches with outcomes from 09/16/2011 to 05/02/2022 focusing on lncRNA application in lung cancer via searching terms of "lncRNA AND lung cancer", "lncRNA AND non-small cell lung cancer", "lncRNA AND drug resistance", "lncRNA AND radio sensitivity". Published articles written in English available to readers were considered.
We summarized significantly differentially-expressed lncRNAs in lung cancer tissues compared with healthy individuals and normal tissues which would become potential biomarkers for lung cancer diagnosis and therapeutic target as a non-invasive detection method.
LncRNAs might be valuable potential diagnostic biomarkers of lung cancer progression.
肺癌是全球癌症相关死亡的主要原因,其发病率很高。传统的肺癌筛查方法,如基于X射线、低剂量计算机断层扫描(LDCT)、正电子发射计算机断层扫描(PET/CT)、电子支气管镜检查和血清肿瘤标志物等,无法满足提高患者生存率的迫切需求。因此,迫切需要用于肺癌早期诊断和预后的生物标志物。研究已鉴定出多种长链非编码RNA(lncRNA),它们在肺癌患者中表达异常,被认为是肺癌诊断和预后评估的潜在生物标志物。本综述旨在探讨lncRNA在非小细胞肺癌(NSCLC)中的作用,以便为肺癌的预后提供见解。
我们检索了PubMed数据库中2011年9月16日至2022年5月2日的相关科研成果,通过搜索词“lncRNA与肺癌”、“lncRNA与非小细胞肺癌”、“lncRNA与耐药性”、“lncRNA与放射敏感性”来关注lncRNA在肺癌中的应用。考虑读者可获取的英文发表文章。
我们总结了与健康个体和正常组织相比,肺癌组织中显著差异表达的lncRNA,作为一种非侵入性检测方法,它们可能成为肺癌诊断的潜在生物标志物和治疗靶点。
LncRNA可能是肺癌进展中有价值的潜在诊断生物标志物。